3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
Triple Negative Breast Neoplasms
9
Sarcoma
5
Neoplasm Metastasis
5
Liposarcoma
3
Inflammatory Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Refractory Solid Tumors
1
Recurrence
1
Metastatic HER2-positive Breast Cancer
1
Ketosis
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
HR+HER2- Breast Cancer
1
HER2-negative Metastatic Breast Cancer
1
HER2-low Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Colorectal Neoplasms
1
Brest Cancer
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
selinexor
1
repotrectinib
1
pembrolizumab
1
pazopanib
1
Trabectedin
1
Suspensions
1
Proton Therapy
1
Magnetic Resonance Spectroscopy
1
Ifosfamide
1
Histamine H2 Antagonists
1
Fluorodeoxyglucose F18
1
Famotidine
1
FAPI-46
1
Doxorubicin
1
Capsules
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solitary Fibrous Tumors
×
eribulin
×
1 year
×
Clear all
No trials found.